Summary
Baxalta Inc (Baxalta) is a biopharmaceutical company that develops, manufactures and commercializes therapies for orphan diseases. The company offers products for the treatment of orphan diseases related to cancer, and hematological and immunological diseases. It offers treatment for hemophilia, bleeding disorders, alpha-1 antitrypsin deficiency, immune deficiencies, burns and shock, other chronic and acute medical conditions, and treatment for acute lymphoblastic leukemia. Baxalta's pipeline includes biologics with innovative mechanisms, and advanced technology platforms such as gene therapy and biosimilars. The company sells its products in North America, South America, Europe and Asia-Pacific. The company conducts research through Baxalta Global Innovation and R&D Center in Cambridge, Massachusetts. Baxalta is headquartered in Bannockburn, Illinois, the US.
Baxalta Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Baxalta Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Baxalta Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Baxalta Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Baxalta Acquires Oncaspar Portfolio from Sigma-Tau Finanziaria for USD900 Million 12
Venture Financing 13
Suppremol Raises US$20.6 Million In Series D Financing 13
AesRx Raises US$1.35 Million In Venture Financing 14
Chatham Therapeutics Secures US$0.2 Million In Venture Financing 15
AesRx Secures An Additional US$0.12 Million In Venture Financing 15
Partnerships 16
TR-Pharm Enters into Distribution Agreement with Sigma-Tau Rare Disease 16
Baxalta Enters into Agreement with Precision Biosciences 16
Baxalta Enters into Agreement with Symphogen 17
Novimmune Enters into Research Agreement with Baxalta 18
Teijin Enters into Co-Development Agreement with Sigma-Tau Pharma for EZN-2279 19
Baxter Enters Into Co-Development Agreement With Chatham Therapeutics For Factor IX Hemophilia B Gene Therapy Treatment 19
Licensing Agreements 20
SuppreMol Exercises Option For Licensing Agreement With Bayerische For RA Antibody 20
Equity Offering 22
Opsona Therapeutics Raises USD10.58 Million in Private Placement of Shares 22
Baxalta Invests in OncoResponse 23
Debt Offering 23
Baxalta Raises USD375 Million in Private Placement of 2% Notes Due 2018 23
Baxalta Raises USD1 Billion in Private Placement of 2.875% Notes Due 2020 24
Baxalta Raises USD500 Million in Private Placement of 3.6% Notes Due 2022 25
Baxalta Raises USD1.75 Billion in Private Placement of 4% Notes Due 2025 26
Baxalta Raises USD1 Billion in Private Placement of 5.25% Notes Due 2045 27
Baxalta Raises USD375 Million in Private Placement of Floating Rate Notes Due 2018 28
Asset Transactions 29
Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta 29
Acquisition 30
Shire Acquires Baxalta for USD32 Billion 30
Baxter International Acquires SuppreMol for USD225 Million 33
Baxter Acquires AesRx 34
Baxter International To Acquire Chatham Therapeutics From Asklepios BioPharma For US$70 Million 34
Baxalta Inc - Key Competitors 37
Key Employees 38
Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42
List of Tables
Baxalta Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Baxalta Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Baxalta Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Baxalta Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Baxalta Acquires Oncaspar Portfolio from Sigma-Tau Finanziaria for USD900 Million 12
Suppremol Raises US$20.6 Million In Series D Financing 13
AesRx Raises US$1.35 Million In Venture Financing 14
Chatham Therapeutics Secures US$0.2 Million In Venture Financing 15
AesRx Secures An Additional US$0.12 Million In Venture Financing 15
TR-Pharm Enters into Distribution Agreement with Sigma-Tau Rare Disease 16
Baxalta Enters into Agreement with Precision Biosciences 16
Baxalta Enters into Agreement with Symphogen 17
Novimmune Enters into Research Agreement with Baxalta 18
Teijin Enters into Co-Development Agreement with Sigma-Tau Pharma for EZN-2279 19
Baxter Enters Into Co-Development Agreement With Chatham Therapeutics For Factor IX Hemophilia B Gene Therapy Treatment 19
SuppreMol Exercises Option For Licensing Agreement With Bayerische For RA Antibody 20
Opsona Therapeutics Raises USD10.58 Million in Private Placement of Shares 22
Baxalta Invests in OncoResponse 23
Baxalta Raises USD375 Million in Private Placement of 2% Notes Due 2018 23
Baxalta Raises USD1 Billion in Private Placement of 2.875% Notes Due 2020 24
Baxalta Raises USD500 Million in Private Placement of 3.6% Notes Due 2022 25
Baxalta Raises USD1.75 Billion in Private Placement of 4% Notes Due 2025 26
Baxalta Raises USD1 Billion in Private Placement of 5.25% Notes Due 2045 27
Baxalta Raises USD375 Million in Private Placement of Floating Rate Notes Due 2018 28
Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta 29
Shire Acquires Baxalta for USD32 Billion 30
Baxter International Acquires SuppreMol for USD225 Million 33
Baxter Acquires AesRx 34
Baxter International To Acquire Chatham Therapeutics From Asklepios BioPharma For US$70 Million 34
Baxalta Inc, Key Competitors 37
Baxalta Inc, Key Employees 38
Baxalta Inc, Subsidiaries 40
List of Figures
Baxalta Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Baxalta Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
